Simplify Logo
BillionToOne

BillionToOne

QCT-based molecular diagnostics for prenatal, oncology

Prenatal Account Executive

Full-Time
$136.9k - $163.3k/yr

+ Commission + Equity Options

Mid
San Antonio, TX, USA
In Person

Southeast San Antonio, Texas; field sales role requiring travel within the territory.

About the job

Requirements
  • Minimum three (3) years of outside field sales experience within the healthcare sector, directly calling upon providers in the specified geographic territory
Responsibilities
  • Increasing utilization of UNITY Fetal Risk Screen and driving market development through direct sales to individual OBGYNs, MFMs, and Genetic Counselors
  • Identifying, developing, and managing commercial relationships with key opinion leaders in medicine and other key healthcare professionals
  • Effectively prospecting and cultivating new business and maintaining key relationships
  • Identifying and capitalizing on commercial opportunities for growth within a specific region or geography – predominately in OBGYN, MFM, and GC clinics, as well as hospital systems and Federally Qualified Health Centers
  • Creating and implementing a strategic business plan to grow utilization quickly in your geography
  • Managing the full lifecycle of the product sales process, including new business development and lead generation
  • Attending local tradeshows, industry conferences and networking events
Desired Qualifications
  • Experience in a start-up environment
  • Women's Health Background
  • Clinical laboratory experience
  • Convertible book of business

About the company

BillionToOne provides molecular diagnostic testing for prenatal screening and cancer monitoring. Its QCT technology detects and measures DNA variations at a single base-pair level, enabling precise analysis across the three billion DNA letters. The main products, Northstar Select and Northstar Response, are tests that help doctors choose the best first-line therapy and track how well treatment is working, respectively. The company markets these services to healthcare providers who perform the tests and use the results to guide patient care. Unlike some rivals, BillionToOne emphasizes high-resolution DNA assessment and scalable diagnostic services through provider partnerships, aiming to improve accuracy, speed, and access. Its mission is to make molecular testing more accurate, efficient, and accessible to all, driven by growth, equality, and teamwork.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Menlo Park, California

Founded

2016

Get referred to BillionToOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $109.4 million, up 64%, with 70% gross margin.
  • Oncology revenue jumped 176% in Q2 2026, validating Northstar beyond prenatal screening.
  • Management guided 2026 revenue to $450–$465 million, signaling sustained commercial momentum.

What critics are saying

  • Illumina sued BillionToOne on May 7, 2026, over three patents in Delaware.
  • Diagnostic adoption still depends on payer coverage; any reimbursement pullback hits growth quickly.
  • If Illumina wins injunctions or royalties, BillionToOne’s UNITY franchise loses margin and launch velocity.

What makes BillionToOne unique

  • BillionToOne’s QCT counts DNA molecules at single-molecule resolution, enabling rare-variant detection.
  • Northstar Origin launched September 1, 2026, predicting tissue-of-origin from one cfDNA blood draw.
  • Unity Confirm launched May 28, 2026, replacing invasive prenatal confirmation with fetal-cell sequencing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Sep 17th, 2026
BillionToOne CEO sells entire direct stake for $3M via pre-planned trading arrangement

BillionToOne CEO Oguzhan Atay sold 30,331 Class A shares on 14 September 2026 for approximately $3 million, liquidating his entire directly held stake in the company. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted in June 2026. The transaction primarily involved a cashless exercise of 24,999 options at $2.80 per share, with immediate sale of resulting shares. Atay's spouse sold an additional 5,332 shares. The weighted average sale price was $99.91. Despite disposing of directly held shares, Atay retains about 500,000 fully vested stock options and holds approximately 157,000 shares indirectly through his spouse. The Menlo Park-based molecular diagnostics company reported $109.4 million revenue in Q2 2026, representing 64% year-over-year growth, with full-year revenue forecast between $450 million and $465 million.

PR Newswire
Sep 1st, 2026
BillionToOne launches Northstar Origin liquid biopsy test to identify cancer tissue of origin

BillionToOne has launched Northstar Origin, a liquid biopsy add-on test that predicts tissue of origin from circulating cell-free DNA for patients with cancer of unknown primary or uncertain cancer diagnosis. The test requires no additional tissue or separate blood draws beyond what's already collected for therapy selection. In a validation study of 1,578 patients, Northstar Origin identified the correct tissue of origin as its top prediction in 87% of cases and within its top three predictions in 91% of cases. The classifier was developed using 6,025 blood samples from advanced cancer patients. The company also expanded its Northstar Select panel from 84 to 102 genes, adding 18 new genes including MTAP deletion. The test is designed to help community oncologists make diagnostic decisions, as roughly 3-5% of new cancer diagnoses present as cancer of unknown primary.

Yahoo Finance
Aug 28th, 2026
BillionToOne CTO sells $1M in shares under pre-planned trading arrangement

David Tsao, co-founder and chief technology officer of BillionToOne, sold 10,000 shares of Class A Common Stock for $1 million on 25 August 2026. The transaction involved a cashless exercise of fully vested stock options at $2.80 per share, with the resulting shares sold at a weighted average price of $100. The sale was executed under a Rule 10b5-1 trading plan adopted in March 2026, indicating it was pre-scheduled rather than discretionary. Tsao retains 1,000 direct shares and 580,000 stock options. BillionToOne, a Menlo Park-based molecular diagnostics company, reported second-quarter revenue of $109.4 million, representing 64% year-over-year growth. The company has a market capitalisation of $4.4 billion and generated $397.4 million in trailing 12-month revenue with $33.5 million in net income.

Yahoo Finance
Aug 6th, 2026
BillionToOne reports $109.4M Q2 revenue, up 64% year-over-year, reiterates 2026 guidance

BillionToOne, a molecular diagnostics company, reported second-quarter 2026 revenue of $109.4 million, up 64% from $66.6 million in the same period last year. Prenatal clinical testing revenue reached $94.2 million, whilst oncology testing revenue surged 176% to $13.7 million. The company delivered 196,000 tests during the quarter, a 35% increase year-over-year. Gross profit margin improved to 70% from 65%. BillionToOne posted operating income of $5.5 million, compared to a $1.6 million loss in Q2 2025. The firm reiterated its full-year 2026 revenue guidance of $450 million to $465 million, representing 48% to 52% growth over 2025. BillionToOne announced plans to expand its Unity Fetal Risk Screen with a 130-gene panel launching 17 August 2026.

Yahoo Finance
Aug 6th, 2026
BillionToOne revenue surges 64% to $109M as oncology jumps 176% and prenatal grows 56%

BillionToOne reported strong second-quarter results for 2026, with total revenue reaching $109.4 million, up 64% year-over-year. Prenatal revenue rose 56% to $95.8 million, while oncology revenue surged 176% to $13.7 million. The company achieved gross margins of 70.5%, up 5 percentage points from the previous year. BillionToOne posted operating income of $5.5 million and net income of $8.1 million, or $0.15 per diluted share. Test volumes increased 35% year-over-year to approximately 196,000 tests, with average selling prices rising 21% to $551 per test. The company generated $9.1 million in cash from operations and $5.1 million in free cash flow. BillionToOne maintained its full-year 2026 revenue guidance of $450 million to $465 million.